Servier acquires DAWN for $21.50.sh cash—a 68% premium to yesterday’s close: https://www.globenewswire.com/news-release/2026/03/06/3251033/0/en/Servier-and-Day-One-Biopharmaceuticals-announce-acquisition-to-expand-Servier-s-rare-oncology-portfolio.html The nominal deal value is $2.5B. Servier, which is private, is the second largest drug company based in France.